Meme Kanserinde tümör baskılayıcı gen adayı olarak DNAJC25

Özet

DNAJC25 geni HSP40 (DNAJ) ailesinin bir üyesidir ve hepatoselüler karsinomada tümör baskılayıcı gen olarak önerilmiş tir. Bu çalışmanın amacı, meme kanserinde DNAJC25 geninin ifadesini, genetik/epigenetik değişimlerini ve prognostikönemini analiz etmekdir. DNAJC25 mRNA ifadesi meme kanseri hücre hatlarında farklılık göstermektedir. Tümörijenik ol mayan meme epitel hücre hattına (MCF 10A) göre, DNAJC25 transkript seviyesi BT-20 ve ZR-75-1 hücre hatlarında upregüleolurken, MDA-MB-231 hücre hattında downregüle olmuştur (P

Abstract

DNAJC25 gene is a member of the HSP40 (DNAJ) family, and it was suggested as a tumor suppressor gene in hepatocellular carcinoma. The aim of this study was to analyze the expression, genetic/epigenetic alterations, and prognostic value of the DNAJC25 gene in breast cancer. DNAJC25 transcript levels are upregulated in BT-20 and ZR-75-1 cell lines and downregulated in MDA-MB-231 cell line compared to the non-tumorigenic mammary epithelial cell line (MCF 10A) (P< 0.05). According to UALCAN in-silico tool, clinical breast cancer samples show significantly reduced levels of DNAJC25 mRNA relative to the normal samples (P=1.47e-02). The Kaplan–Meier plotter tool shows that high DNAJC25 expression is favorable for post-progression survival in breast cancer (P=0.0035). Point mutations or copy number variations of DNAJC25 are uncommon in clinical breast cancer samples. Combined bisulfite restriction analysis (COBRA) results showed that DNAJC25promoter is not methylated in breast cell lines. Promoter hypomethylation was also observed in normal and tumor clinical samples (Beta-value